Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis

• Status: Completed
• Trial end date: 0000-00-00
• Target enrollment: 467
• Participant gender: Both

Summary

The purpose of this open-label study is to evaluate the long-term safety and efficacy of ABP 501.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Adalimumab
• Last Updated: 2016-04-21

Criteria

Inclusion Criteria:

• Subject was randomized into protocol 20120262 and has completed the week 26 visit

Exclusion Criteria:

• Subject experienced a serious adverse event (SAE) or an adverse event (AE) in the 20120262 study that could cause extension treatment to be detrimental

• Subject has completed study 20120262 but cannot be dosed within 4 weeks of the week 26 visit of study 20120262

• Current infection requiring the use of oral or intravenous antibiotics

Other Inclusion/Exclusion criteria may apply